Cart

Cart


testPatients must have histologically confirmed rare cancer identified, that did not have a match to a molecularly-guided therapy on EAY131 “NCIMATCH” protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, “NCIMATCH”. Patients who meet criteria in and are determined to have a rare cancer with unknown primary site are eligible under Cohort #32 (Tumor of unknown primary (Cancer of Unknown Primary; CuP), provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated crosssectional imaging of the chest, abdomen, and pelvis.



Research & Trial Information

SCHEMA S1605

Protocol#: ECOG – EAQ152 – COMET

Cancer Type:  Genomic Based Trial

Eligibility Criteria (Step 1) – Primary Intervention Study (RCT)

  1. Patients must be registered to the first screening step (Step 0) for the NCI-MATCH trial (EAY131).
  2. Patients must speak English.
  3. Patients must have web and e-mail access.
  4. Patients must have not received his/her MATCH tumor genetic testing results.

Eligibility Criteria (Step 2) – Secondary Genetic Counseling Sub study

  1. Patients must meet the eligibility requirements in Section 3.1 (except for Section 3.1.3 and 3.1.4) and have had the results from their tumor genetic testing on the NCI-MATCH study shared with them.
  2. Patients must have a potential germline mutation, as determined by the NCI-MATCH tumor profiling assay, and must meet one of the following criteria:
    • Patient’s tumor contains one of the following genetic variants: BRCA1, BRCA2, MLH1, MSH2, RB1, RET, STK11, TSC1, TSC2, VHL, CDH1, CDKN2A
    • Patient has an APC mutation and NOT colon cancer
    • Patient has an APC mutation, colon cancer and a history of polyposis
    • Patient has a PTEN mutation and NOT uterine cancer
    • Patient has a TP53 mutation AND either h/o sarcoma, breast cancer (< 40 years old), adrenal cancer, or glioblastoma.
  3. Patients must be able to speak English and hear by phone.

Genesys Hurley Cancer Institute

302 Kensington Avenue
Flint, MI 48503

810-762-8226 | 888-762-8675

Genesys Health System
Hurley Medical Center
Michigan Cancer Consortium

Newsletter

Ⓒ 2018 Genesys Hurley Cancer Institute | All Rights Reserved.

Cart

Cart